头颈部鳞状细胞癌的个性化医疗：联合治疗的理论依据
Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies.
作者信息
Birkeland Andrew C, Brenner J Chad
机构信息
Department of Otolaryngology - Head and Neck Surgery, The University of Michigan Medical School, Ann Arbor, MI.
Department of Otolaryngology - Head and Neck Surgery, The University of Michigan Medical School, Ann Arbor, MI; Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, MI.
出版信息
Med Res Arch. 2015;3(3). doi: 10.18103/mra.v0i3.77.
Abstract
Personalized medicine, in which individual tumor genetics drive the selection of targeted therapies and treatment plans for each patient, has recently emerged as the next generation of cancer therapy. Unfortunately, personalized medicine trials have had limited success in tumors that have complex combinations of disruptive genomic events, which drive differential responses to targeted therapies. Here, we will use head and neck squamous cell carcinoma as a model for genetically complex disease and discuss novel approaches to enhance personalized medicine trials for these complicated cases.
摘要
个性化医疗，即根据个体肿瘤遗传学为每位患者选择靶向治疗和治疗方案，最近已成为新一代癌症治疗方法。不幸的是，在具有破坏性基因组事件复杂组合的肿瘤中，个性化医疗试验取得的成功有限，这些基因组事件导致对靶向治疗产生不同反应。在此，我们将以头颈部鳞状细胞癌作为遗传复杂疾病的模型，并讨论针对这些复杂病例加强个性化医疗试验的新方法。
相似文献
1
Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies.头颈部鳞状细胞癌的个性化医疗：联合治疗的理论依据
Med Res Arch. 2015;3(3). doi: 10.18103/mra.v0i3.77.
2
A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.头颈部鳞状细胞癌个性化治疗在研药物综述。
Expert Rev Precis Med Drug Dev. 2016;1(4):379-385. doi: 10.1080/23808993.2016.1208050. Epub 2016 Jul 15.
3
Genomically personalized therapy in head and neck cancer.头颈部癌的基因组个性化治疗
Cancers Head Neck. 2016 Jun 9;1:2. doi: 10.1186/s41199-016-0004-y. eCollection 2016.
4
Defining the genomic landscape of head and neck cancers through next-generation sequencing.通过下一代测序技术定义头颈癌的基因组格局。
Oral Dis. 2015 Jan;21(1):e11-24. doi: 10.1111/odi.12246. Epub 2014 Apr 30.
5
Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.在经靶向测序定义的流行病学低风险患者中，成纤维细胞生长因子家族异常作为头颈部鳞状细胞癌的一种假定驱动因素。
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.
6
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.改变模式：喉鳞状细胞癌靶向治疗的潜力
Cancer Biol Med. 2016 Mar;13(1):87-100. doi: 10.28092/j.issn.2095-3941.2016.0010.
7
Harnessing massively parallel sequencing in personalized head and neck oncology.利用大规模平行测序进行个体化头颈部肿瘤学研究。
J Dent Res. 2014 May;93(5):437-44. doi: 10.1177/0022034514524783. Epub 2014 Feb 20.
8
Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.肿瘤切片的短期培养揭示了人类头颈部鳞状细胞癌对靶向治疗的异质性敏感性。
BMC Cancer. 2016 Apr 16;16:273. doi: 10.1186/s12885-016-2318-x.
9
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.将下一代测序纳入常规临床护理，以指导头颈部鳞状细胞癌的治疗。
Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.
10
Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.头颈部鳞状细胞癌的遗传决定因素及其对全球个性化医疗的影响。
Genes Cancer. 2016 May;7(5-6):182-200. doi: 10.18632/genesandcancer.110.
引用本文的文献
1
Combination Treatment of Withalongolide a Triacetate with Cisplatin Induces Apoptosis by Targeting Translational Initiation, Migration, and Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.榄香烯三乙酸酯联合顺铂通过靶向翻译起始、迁移和上皮间质转化诱导头颈部鳞状细胞癌凋亡。
Nutrients. 2022 Dec 19;14(24):5398. doi: 10.3390/nu14245398.
2
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.头颈部癌症中的精准医学和下一代测序的当前趋势。
Curr Treat Options Oncol. 2022 Feb;23(2):254-267. doi: 10.1007/s11864-022-00942-8. Epub 2022 Feb 23.
3
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.推进 PI3K 通路抑制剂用于个性化 chordoma 治疗的基本原理。
J Neurooncol. 2020 Mar;147(1):25-35. doi: 10.1007/s11060-020-03418-7. Epub 2020 Feb 17.
4
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.口腔鳞状细胞癌 UM-SCC 细胞系的基因组图谱。
Oral Oncol. 2018 Dec;87:144-151. doi: 10.1016/j.oraloncology.2018.10.031. Epub 2018 Nov 8.
5
Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.鼻窦畸胎癌肉瘤的发病机制分析揭示了可靶向治疗的β-连环蛋白过表达和一种β-连环蛋白突变。
J Neurol Surg B Skull Base. 2017 Aug;78(4):346-352. doi: 10.1055/s-0037-1601320. Epub 2017 Mar 27.
6
Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.黏液表皮样癌中Crtc1/3-Maml2融合状态、分级与生存情况的相关性
Oral Oncol. 2017 May;68:5-8. doi: 10.1016/j.oraloncology.2017.02.025. Epub 2017 Mar 10.
7
Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.监测头颈部鳞状细胞癌中精准医学驱动的PD-1/PD-L1靶向治疗的潜力。
J Cancer. 2017 Feb 9;8(3):332-344. doi: 10.7150/jca.17547. eCollection 2017.
8
A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.头颈部鳞状细胞癌个性化治疗在研药物综述。
Expert Rev Precis Med Drug Dev. 2016;1(4):379-385. doi: 10.1080/23808993.2016.1208050. Epub 2016 Jul 15.
9
Differential compensation mechanisms define resistance to PI3K inhibitors in amplified HNSCC.差异补偿机制决定了扩增型头颈部鳞状细胞癌对PI3K抑制剂的耐药性。
Otorhinolaryngol Head Neck Surg. 2016;1(2):44-50. doi: 10.15761/ohns.1000111. Epub 2016 Jun 7.
10
Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.头颈部鳞状细胞癌的遗传决定因素及其对全球个性化医疗的影响。
Genes Cancer. 2016 May;7(5-6):182-200. doi: 10.18632/genesandcancer.110.
本文引用的文献
1
Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.在经靶向测序定义的流行病学低风险患者中，成纤维细胞生长因子家族异常作为头颈部鳞状细胞癌的一种假定驱动因素。
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.
2
Getting personal: Head and neck cancer management in the era of genomic medicine.个性化医疗：基因组医学时代的头颈癌管理
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E2250-8. doi: 10.1002/hed.24132. Epub 2015 Aug 13.
3
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
4
Comprehensive genomic characterization of head and neck squamous cell carcinomas.头颈部鳞状细胞癌的综合基因组特征分析
Nature. 2015 Jan 29;517(7536):576-82. doi: 10.1038/nature14129.
5
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.优化临床实践中的转化肿瘤学：加速药物研发进展的策略。
Cancer Treat Rev. 2015 Feb;41(2):129-35. doi: 10.1016/j.ctrv.2014.12.004. Epub 2014 Dec 16.
6
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.靶向头颈部鳞状细胞癌中的PI3K/AKT/mTOR信号通路。
Oral Oncol. 2015 Apr;51(4):291-8. doi: 10.1016/j.oraloncology.2014.11.012. Epub 2014 Dec 17.
7
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.哌柏西利联合来曲唑与来曲唑单药一线治疗雌激素受体阳性、HER2 阴性、晚期乳腺癌（PALOMA-1/TRIO-18）的随机 2 期研究。
Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
8
Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq.通过RNA测序对福尔马林固定、石蜡包埋的肾细胞癌进行全转录组分析。
BMC Genomics. 2014 Dec 11;15(1):1087. doi: 10.1186/1471-2164-15-1087.
9
HER2 as a therapeutic target in head and neck squamous cell carcinoma.人表皮生长因子受体2作为头颈部鳞状细胞癌的治疗靶点
Clin Cancer Res. 2015 Feb 1;21(3):526-33. doi: 10.1158/1078-0432.CCR-14-1432. Epub 2014 Nov 25.
10
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
Zotero 插件